GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS
2026 · 1st Quarter (Jan 1 - Mar 31)
BIOMARIN PHARMACEUTICAL INC.
Filed by BIOMARIN PHARMACEUTICAL INC..
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 20, 2026
- Income
- Not reported
- Expenses
- $530,000.00
- Registrant
- BIOMARIN PHARMACEUTICAL INC.
- Filing UUID
- 5ff791c9-7687-4a66-807d-011eba5b3746
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.